Ciprofloxacin Oral, Injection products
Ciprofloxacin Oral, Injection products
Recognized Interpretive Criteria
Additional FDA-identified interpretive criteria
|
|
Minimum Inhibitory |
Disk Diffusion |
||||
|---|---|---|---|---|---|---|
|
Pathogen |
S |
I |
R |
S |
I |
R |
|
Enterobacteriaceae |
M100 standard is recognized |
|||||
|
Pseudomonas aeruginosa |
M100 standard is recognized |
|||||
|
Staphylococcus spp. |
M100 standard is recognized |
|||||
|
Enterococcus spp. |
M100 standard is recognized |
|||||
|
Haemophilus influenzae and |
M100 standard is recognized |
|||||
|
Neisseria gonorrhoeae |
M100 standard is recognized |
|||||
|
Streptococcus pneumoniae |
≤1 |
2 |
≥4 |
≥21 |
16-20 |
≤15 |
|
Streptococcus spp. β- |
≤1 |
2 |
≥4 |
≥21 |
16-20 |
≤15 |
|
Bacillus anthracis |
M45 standard is recognized |
- |
- |
- |
||
|
Yersinia pestis |
M45 standard is recognized |
- |
- |
- |
||
S = Susceptible; I = Intermediate; R = Resistant
Exceptions to the recognized standard of CLSI M100
For these bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:
Acinetobacter spp.
Other Non-Enterobacteriaceae
Neisseria meningitides